Clinical Trials Using Poziotinib
Clinical trials are research studies that involve people. The clinical trials on this list are studying Poziotinib. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Phase 2 Study of Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
This is a Phase 2, open-label, multicenter study to evaluate the efficacy and the safety / tolerability of poziotinib in four patient cohorts for up to 174 previously treated NSCLC patients with any systemic therapy (87 patients with EGFR exon 20 insertion mutations and 87 patients with HER2 exon 20 insertion mutations) and up to 140 treatment-naive NSCLC patients (70 patients with EGFR exon 20 insertion mutations and 70 patients with HER2 exon 20 insertion mutations).
Location: 22 locations
Poziotinib in Treating Patients with Stage IV or Recurrent Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Mutation
This phase II trial studies how well poziotinib works in treating patients with non-small lung cancer with EGFR or HER2 exon 20 mutation that is stage IV or has come back. Poziotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Location: M D Anderson Cancer Center, Houston, Texas